Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Halliburton Company (HAL) vs Invesco Ltd. (IVZ) Price & Performance

Halliburton CompanyTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

Halliburton Company vs Invesco Ltd. — how do they compare? Halliburton Company trades at $32.44 (market cap $26.45B), while Invesco Ltd. trades at $30.09 (market cap $13.47B). The key difference: Halliburton Company is the larger of the two by market cap, and Invesco Ltd. pays the higher dividend (2.82%). Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Invesco Ltd. for 77 Days on average.

HALIVZ
Market Cap
$26.45B$13.47B
Volume
11,229,2744,447,526
Sector
EnergyFinancials
52-Week High
$42.98$33.31
52-Week Low
$21.82$22.44
Typical Hold Time
89 Days77 Days
Enterprise Value
$32.60B$23.63B
Dividend Yield
2.14%2.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Halliburton Company

Halliburton (HAL) trades at $32.57, down 0.46% on the day, amid a bearish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent news highlights expansion in Venezuela and a major contract win in Cyprus, signaling growth initiatives. Financials show solid profitability with a net income margin of 7.16% and a P/E ratio of 16.62, though 2025 revenue dipped slightly to $22.18 billion.

The outlook is supported by strong analyst consensus with a $43.11 price target and 73% buy ratings, but risks include oil price volatility and execution challenges in new markets. Cash flow trends have been mixed, with 2025 net cash flow negative $412 million, though 2026 projects a return to positive territory.

Invesco Ltd.

Invesco (IVZ) trades at $30.09, down 0.95% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $281.70 million for 2025 despite revenue growth to $6.38 billion, with a negative net margin of -0.93%. Recent earnings have been mixed, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, while Q3 2026 results are pending. Positive developments include strong operating cash flow of $1.53 billion in 2025 and the expansion of its QQQ ETF suite.

The outlook is cautiously optimistic, supported by a consensus price target of $33.71 and no sell ratings among analysts. Key opportunities lie in continued AUM growth and ETF innovation, but risks include profitability challenges and market volatility. The stock's current price near support at $30.00 suggests limited downside if fundamentals improve with upcoming earnings.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HAL
79% Buy21% Sell
Avg holding period · 89 Days
IVZ

No sentiment data available yet.

Top news

Latest headlines on both assets

About Halliburton Company

Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.

Read more on HAL →

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →